# Pathway to Cures

Pathway to Cures is a Venture Philanthropy Fund based in New York, United States.

## Overview

- **Organization type:** Venture Philanthropy Fund
- **Headquarters:** New York, United States
- **Region:** North America
- **Address:** 1230 Avenue of the Americas, 16th Floor, New York, NY 10020
- **Founded:** 2022
- **Assets under management:** Undisclosed
- **Website:** www.pathwaytocures.org
- **LinkedIn:** https://www.linkedin.com/company/pathway-to-cures

## Regulatory record

- **Reports private funds:** No

## About

Pathway to Cures (P2C) is the National Bleeding Disorders Foundation’s venture philanthropy fund. It uses a mission-oriented investment model to drive progress and innovation across multiple inheritable blood and bleeding disorders. P2C focuses on filling the funding gap and investing in transformational therapies and technologies for all inheritable blood and bleeding disorders.

## Sectors

- Healthcare Services
- Digital Health

## People

- Teri Willey — Managing Director & Officer, Pathway to Cures, National Bleeding Disorders Foundation
- Tim Brent — Venture Principal, Pathway to Cures, National Bleeding Disorders Foundation

## Questions

### Who runs investment decisions at Pathway to Cures?

Managing Director & Officer Teri Willey leads the fund day-to-day, supported by Venture Principal Tim Brent and a cross-functional group of investment professionals, scientific researchers, and medical volunteers. The team operates within NBDF's governance framework but makes independent investment decisions.

### How does Pathway to Cures source its deal flow?

P2C leverages the National Bleeding Disorders Foundation's deep scientific and clinical network to identify early-stage assets addressing inheritable blood and bleeding disorders. By connecting with researchers, clinicians, and advocacy communities, the fund surfaces companies that are often overlooked by traditional venture capital.

### Is Pathway to Cures structured as a traditional private equity fund?

No. P2C is a 501(c)(3) venture philanthropy fund, not a for-profit private equity vehicle. All donations flow into mission-aligned investments, and any financial returns are reinvested into the portfolio. Neither management nor donors receive capital distributions.

### Does Pathway to Cures require co-investment from traditional venture capital alongside its own capital?

The fund explicitly seeks to attract follow-on capital from traditional VC, biotech, and pharma by de-risking early-stage science through its own due diligence and NBDF's expert network. P2C's own commitment aims to validate opportunities for subsequent private-sector rounds.

### Which sectors or disease areas does Pathway to Cures target?

P2C invests exclusively in companies developing therapies and technologies for inheritable blood and bleeding disorders. This includes conditions such as von Willebrand disease and platelet disorders, explicitly excluding areas outside that disease scope.

### What is the relationship between Pathway to Cures and the National Bleeding Disorders Foundation?

NBDF is both P2C's parent organization and a donor, supplying critical scientific and advocacy resources. Operationally, P2C functions independently with its own investment team, using NBDF's relationships and expertise to inform deal selection and diligence.

### What is the minimum donation to participate in Pathway to Cures?

P2C asks for a minimum donation of $500,000 from individuals, groups, or institutions. This threshold is designed to concentrate capital and accelerate portfolio growth across multiple inheritable blood and bleeding disorders.

## Related profiles

- [Pathway Financial Advisors](https://altss.com/profile/pathway-financial-advisors)
- [Pathway Ventures](https://altss.com/profile/pathway-ventures)

---

Last updated: 2026-08-11T15:07:41.444Z

Canonical page: https://altss.com/profile/pathway-to-cures

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology